Polar Capital Hlthcare Discv I Acc
Healthcare and BiotechnologyPricing frequency
Daily
Dealing cut off time
13:45
Type
OEIC
Yield
–
NAV
£12.98
Income frequency
-
Ongoing charge
1.08%
Latest actual NAV date
13-11-2026
ISIN
IE00BJXT2B13
UCITS
Yes
Growth of 10k
Asset allocation
Top 10 holdings
| Holdings 30/09/2026 | % of assets |
|---|---|
| Guardant Health Inc | 4.12 |
| BridgeBio Pharma Inc | 3.74 |
| Repligen Corp | 3.72 |
| HealthEquity Inc | 3.39 |
| Madrigal Pharmaceuticals Inc | 3.05 |
| BrightSpring Health Services Inc | 2.86 |
| Enliven Therapeutics Inc | 2.65 |
| Roivant Sciences Ltd Ordinary Shares | 2.59 |
| Hikma Pharmaceuticals PLC | 2.37 |
| Xenon Pharmaceuticals Inc | 2.36 |
Investment objective
The investment objective of the Fund is to achieve long term capital growth. The Fund will seek to achieve its investment objective by investing in a globally diversified portfolio of healthcare companies which may be listed or traded on a Regulated Market. The Fund may invest in excess of 20% of its Net Asset Value in emerging markets.
This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Learn more about SDR.